Please assess the completion status of the following clinical trial:

Trial Title: Controlled Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male aged ≥18 years old~* For potentially childbearing female, only those with effective contraception (contraception pill, implant and intrauterine device) could be included~* Patient who need skin graft ( height equal to or greater than 100cm2 and thickness 1.2mm) after surgery excision~* Patients with social security~* Patients able to understand and follow the trial instructions~* Patients who have signed an informed consent~Exclusion Criteria:~* Patients with an history of cancers except basal and squamous cell, cutaneous carcinoma.~* Patients suffering from uncontrolled metabolic disease (for instance diabete), from a psychiatric disorder not treated, with severe arteritis of lower and/or upper limbs, treated with anticoagulant (unless treatment stops 7 days before the surgery), with severe venous insufficiency, suffering of severe polyneuropathy, with known allergy to antibiotics,~* Patients with an allergic predisposition or known allergy to bovine collagen or silicone~* Patients receiving corticosteroids, immunosuppressive or cytotoxic agents unless treatment stops 4 weeks before the surgery~* Patients contraindicated with local anesthetic used in STSG process of his investigator center~* Patients with systemic infection (all grade defined by CTCAE Common Terminology Criteria for Adverse Event V4.03) at surgery visit will not be included in this trial because of the contraindication of the surgical gesture.~* Patient intolerant to the conventional treatment (JELONET®)~* Patient intolerant to URGO TUL®~* Patient intolerant to TELFA®~* Patient intolerant to the stretchable strip (HYPAFIX® or NYLEX®)~* Pregnant or breast-feeding women~* Patients participating in clinical trial~* Vulnerable people: persons deprived of liberty; under trusteeship or under curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biological Dressing (Type: EXPERIMENTAL): It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:~* Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.~* The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements
- Paraffin Gauze Dressing (Type: ACTIVE_COMPARATOR): It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy